Date:11/15/2012

976Table 160: Active Biotech's Included Antibody Drugs in Oncology and Competitive Fall-Out 981Table 161: Adherex's Included Antibody Drugs in Oncology and Competitive Fall-Out 985Table 162: Affibody's Included Antibody Drugs in Oncology and Competitive Fall-Out 991Table 163: Affimed Therapeutics' Included Antibody Drugs in Oncology and Competitive Fall-Out 999Table 164: Affitech's Included Antibody Drugs in Oncology and Competitive Fall-Out 1008Table 165: AGY Therapeutics' Included Antibody Drugs in Oncology and Competitive Fall-Out 1014Table 166: Aida Pharmaceuticals' Included Antibody Drugs in Oncology and Competitive Fall-Out 1019Table 167: Alder Biopharmaceuticals' Included Antibody Drugs in Oncology and Competitive Fall-Out 1025Table 168: Alethia Biotherapeutics' Included Antibody Drugs in Oncology and Competitive Fall-Out 1031Table 169: Alexion's Included Antibody Drugs in Oncology and Competitive Fall-Out 1035Table 170: Algeta's Included Antibody Drugs in Oncology and Competitive Fall-Out 1041Table 171: ALSP's Included Antibody Drugs in Oncology and Competitive Fall-Out 1049Table 172: Altor BioScience's Included Antibody Drugs in Oncology and Competitive Fall-Out 1054Table 173: Amgen's Included Antibody Drugs in Oncology and Competitive Fall-Out 1063Table 174: Amorfix Life Sciences' Included Antibody Drugs in Oncology and Competitive Fall-Out 1088Table 175: Antisoma's Included Antibody Drugs in Oncology and Competitive Fall-Out 1093Table 176: Aphios' Included Antibody Drugs in Oncology and Competitive Fall-Out 1099Table 177: Apricus Biosciences' Included Antibody Drugs in Oncology and Competitive Fall-Out 1106Table 178: Arana Therapeutics' Included Antibody Drugs in Oncology and Competitive Fall-Out 1112Table 179: Arca biopharma's Included Antibody Drugs in Oncology and Competitive Fall-Out 1116Table 180: Areva's Included Antibody Drugs in Oncology and Competitive Fall-Out 1122Table 181: arGEN-X's Included Antibody Drugs in Oncology and Competitive Fall-Out
'/>"/>

SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
3. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
4. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
5. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
6. Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS
7. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
10. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
11. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium